Mariana Nacht - Nov 16, 2022 Form 4 Insider Report for LogicBio Therapeutics, Inc. (LOGC)

Role: Chief Scientific Officer
Signature: /s/ Frederic Chereau, as Attorney-in-Fact
Stock symbol: LOGC
Transactions as of: Nov 16, 2022
Transactions value $: $0
Form type: 4
Date filed: 11/17/2022, 08:12 PM
Previous filing: Mar 3, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LOGC	Stock Option (right to buy)	Disposed to Issuer		-100K	-100%		0	Nov 16, 2022	Common Stock	100K	$0.70	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Mariana Nacht is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	The options were granted on March 1, 2022. The options were scheduled to vest over four years: 25% of the options were scheduled to vest on the first anniversary of the grant date with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the LogicBio Therapeutics, Inc. (the "Company") on each vesting date.
F2	Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022, by and among the Company, Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022.

Content

The options were granted on March 1, 2022. The options were scheduled to vest over four years: 25% of the options were scheduled to vest on the first anniversary of the grant date with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the LogicBio Therapeutics, Inc. (the "Company") on each vesting date.

Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022, by and among the Company, Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022.